SCHEMBL2146452

SCHEMBL2146452

N#Cc1ccsc1-c1c(C(N)=O)c2ccccc2n1-c1ccc(O)cc1

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 4/20 0.36
KMT2A Q03164 4/20 0.36
ALDH1A1 P00352 3/20 0.36
SMN1; SMN2 Q16637 2/20 0.36
MAPT P10636 2/20 0.36
GAA P10253 1/20 0.36
USP14 P54578 2/20 0.35
ESR2 Q92731 1/20 0.34
KDM4E B2RXH2 2/20 0.33
POLB P06746 1/20 0.33
CASP3 P42574 1/20 0.33
SENP8 Q96LD8 1/20 0.33
SENP7 Q9BQF6 1/20 0.33
SENP6 Q9GZR1 1/20 0.33
EGFR P00533 1/20 0.33
SRC P12931 1/20 0.33
TDP2 O95551 1/20 0.33
STAT3 P40763 1/20 0.32
SCN9A Q15858 1/20 0.32
SLC22A12 Q96S37 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2146335 0.83 ESR2 (0.43) ALDH1A1SMN1; SMN2USP14ESR2KDM4E
SCHEMBL1076787 0.83 KDM4E (0.39) MEN1KMT2AALDH1A1SMN1; SMN2MAPT
SCHEMBL2146618 0.80 USP14 (0.34) ALDH1A1SMN1; SMN2MAPTGAAUSP14
SCHEMBL2146457 0.77 ESR2 (0.34) MEN1KMT2AALDH1A1SMN1; SMN2MAPT
SCHEMBL2146608 0.77 USP14 (0.39) ALDH1A1SMN1; SMN2MAPTUSP14KDM4E
SCHEMBL1075323 0.76 AGTR1 (0.46) MEN1KMT2AALDH1A1SMN1; SMN2MAPT
SCHEMBL30385406 0.76 AGTR1 (0.46) MEN1KMT2AALDH1A1SMN1; SMN2MAPT
SCHEMBL28285318 0.74 IL1R1 (0.46) MEN1KMT2AALDH1A1SMN1; SMN2MAPT
SCHEMBL1075038 0.72 ESR2 (0.39) MEN1KMT2AALDH1A1MAPTGAA
SCHEMBL1077219 0.71 EGFR (0.42) KMT2ASMN1; SMN2MAPTGAAESR2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110201555-A1 NOVEL ESTROGEN RECEPTOR LIGANDS KARO BIO AB (SE) 2011-08-18 US claimed
EP-2346824-A1 NOVEL ESTROGEN RECEPTOR LIGANDS KARO BIO AB (SE) 2011-07-27 EP claimed
WO-2010031852-A1 NOVEL ESTROGEN RECEPTOR LIGANDS KARO BIO AB (SE) 2010-03-25 WO claimed
US-20110201555-A1 NOVEL ESTROGEN RECEPTOR LIGANDS KARO BIO AB (SE) 2011-08-18 US disclosed
EP-2346824-A1 NOVEL ESTROGEN RECEPTOR LIGANDS KARO BIO AB (SE) 2011-07-27 EP disclosed
WO-2010031852-A1 NOVEL ESTROGEN RECEPTOR LIGANDS KARO BIO AB (SE) 2010-03-25 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110201555-A1 NOVEL ESTROGEN RECEPTOR LIGANDS ESR1, ESRRA, GPER1 MEN1 2586/4885KMT2A 1814/4885ALDH1A1 1197/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.